Characterization of drug conjugates
Characterize and compare binding of your drug conjugates
Antibody drug conjugates, radiotracers and radioimmunotherapy all rely on the incorporation of a secondary molecule or nuclide to the original ligand. LigandTracer enables a detailed investigation of possible conjugation effects and helps you choose the best alternative.
Gained information
- How conjugations affect the affinity
- How conjugations affect the binding kinetics
- in vitro predictions of radiotracers
- Possible variations in binding mode
- Batch-to-batch variation
- Ligand heterogeneity
Key publications
These publications illustrate the application well. Click here for more examples.
Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.
Garousi J, Huizing FJ, Vorobyeva A, Mitran B, Andersson KG, Dahlsson Leitao C, Frejd FY, Löfblom J, Bussink J, Orlova A, Heskamp S, Tolmachev V.
Sci Rep. 2019. 9:14907.
Summary
PubMed
Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.
Mortensen AC, Spiegelberg D, Haylock AK, Lundqvist H, Nestor M.
Int J Oncol. 2018. 52(6):1875-1885.
Summary
PubMed
Examples of insights
